OUTER space and the Bronze Age do not sit well in the same sentence – they may both have existed at the same time, but anyone based on Earth back then would not have known much, or anything, about what lies beyond.
Spanish-made anti-Covid drug effective against new and future viral mutations
02/02/2021
A MEDICATION made in Spain has been found to reduce the viral load in Covid-19 patients by almost 100% by inhibiting a protein known as eEF1A.
According to Science magazine, the 'powerful' activity of Plitidepsin – branded on the market as Aplidin – developed by PharmaMar is administered intravenously and has a 'limited toxicity level', meaning few or no side-effects.
It cuts the replication of viral particles in the lungs by over 99%, according to tests on animals, and now it is being trialled on humans, it has been found to be well-tolerated as well as effective.
The dose needed for Covid patients is 'significantly lower' than that given in trials, and which only produced minor and very bearable reactions.
It acts by blocking the protein eEF1A, which is automatically present in human cells but which is 'used' by the SARS-CoV-2 virus to reproduce and spread throughout the body.
“We believe that our data, and the positive initial results of clinical trials by PharmaMar, suggest that Plitidepsin should be seriously considered as a candidate for more extended trials in treating Covid-19,” Science magazine says.
Head of the Faculty of Microbiology at the Icahn School of Medicine in Mount Sinai, Spaniard Adolfo García-Sastre, is one of the trial participants and says: “Of all the SARS-CoV-2 inhibitors we've classified in tissue cultivating and in animal models since we started our research into the virus, Plitidepsin has proven to be the most powerful, which highlights its great potential as a therapy in treating Covid-19.”
Dr García-Sastre's colleague, Professor Kris M. White, says the major advantage of Plitidepsin is that it targets a protein present in the human body, rather than one present in the virus itself.
This means it does not allow the virus to evolve in order to become resistant to drugs, as has been the case with the appearance of the British and South African mutations – Plitidepsin makes the human cell protein needed by the different variants of the Covid-causing virus inaccessible to them, meaning they cannot 'save themselves' or continue to reproduce by evolving.
PharmaMar, a Spanish company, is working with the laboratory run by Professor White, Dr García Sastre and Dr Thomas Zwaka, and also with California-San Francisco State University's Quantitative Biosciences Institutee's Kevan Shokat and Nevan Krogan, and Dr Marco Vignuzzi from Paris' Pasteur Institute.
Related Topics
A MEDICATION made in Spain has been found to reduce the viral load in Covid-19 patients by almost 100% by inhibiting a protein known as eEF1A.
According to Science magazine, the 'powerful' activity of Plitidepsin – branded on the market as Aplidin – developed by PharmaMar is administered intravenously and has a 'limited toxicity level', meaning few or no side-effects.
It cuts the replication of viral particles in the lungs by over 99%, according to tests on animals, and now it is being trialled on humans, it has been found to be well-tolerated as well as effective.
The dose needed for Covid patients is 'significantly lower' than that given in trials, and which only produced minor and very bearable reactions.
It acts by blocking the protein eEF1A, which is automatically present in human cells but which is 'used' by the SARS-CoV-2 virus to reproduce and spread throughout the body.
“We believe that our data, and the positive initial results of clinical trials by PharmaMar, suggest that Plitidepsin should be seriously considered as a candidate for more extended trials in treating Covid-19,” Science magazine says.
Head of the Faculty of Microbiology at the Icahn School of Medicine in Mount Sinai, Spaniard Adolfo García-Sastre, is one of the trial participants and says: “Of all the SARS-CoV-2 inhibitors we've classified in tissue cultivating and in animal models since we started our research into the virus, Plitidepsin has proven to be the most powerful, which highlights its great potential as a therapy in treating Covid-19.”
Dr García-Sastre's colleague, Professor Kris M. White, says the major advantage of Plitidepsin is that it targets a protein present in the human body, rather than one present in the virus itself.
This means it does not allow the virus to evolve in order to become resistant to drugs, as has been the case with the appearance of the British and South African mutations – Plitidepsin makes the human cell protein needed by the different variants of the Covid-causing virus inaccessible to them, meaning they cannot 'save themselves' or continue to reproduce by evolving.
PharmaMar, a Spanish company, is working with the laboratory run by Professor White, Dr García Sastre and Dr Thomas Zwaka, and also with California-San Francisco State University's Quantitative Biosciences Institutee's Kevan Shokat and Nevan Krogan, and Dr Marco Vignuzzi from Paris' Pasteur Institute.
Related Topics
More News & Information
A FIRM annual fixture for fans of the latest technology, the Barcelona-based Mobile World Congress (MWC) never fails to blow visitors' minds with creations they didn't know they needed. And these cutting-edge...
A HOLLYWOOD legend joining folk-dancers from Asturias and showing off her fancy footwork in the street is not a scene your average Oviedo resident witnesses during his or her weekly shop. Even though their northern...
Debate over banning short-distance flights takes off, but the cons outweigh the pros